AB-423 / Arbutus - LARVOL DELTA

[VIRTUAL] DISCOVERY OF KL060332, A POTENTIAL BEST-IN-CLASS HBV CAPSID INHIBITOR (AASLD 2020) - "The pharmacokinetic properties of AB-423 were evaluated in age- and weight-matched animal species, including mice, rats, dog and monkey... KL060332 is a novel oral HBV capsid inhibitor with potent antiviral activity and promising safety profiles that support advancing this candidate to clinical development. Preclinical data suggests KL060332 has the potential to be the best-in-class. Phase 1a dose escalation study of KL060332 is ongoing, and interim results will be available by October 2020."

Hepatitis B • Hepatology • Infectious Disease

Preclinical profile of AB-423, an inhibitor of Hepatitis B virus pgRNA encapsidation. (PubMed, Antimicrob Agents Chemother) - "A 7-dayadministration of AB-423 in a hydrodynamic injection mouse model of HBV model resulted in a dose-dependent reduction in serum HBV DNA levels and combination with ETV or ARB-1467 resulted in a trend towards greater antiviral activity than either agent alone consistent with the results of thecombination studies. The overall preclinical profile of AB-423 supports further evaluation for safety, pharmacokinetics and antiviral activity in CHB patients."

Journal • Preclinical